Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 48: 1272-1278, 2002;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (3)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Grzeda, B. R.
Right arrow Articles by Maggiore, J. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Grzeda, B. R.
Right arrow Articles by Maggiore, J. A.
Related Collections
Right arrow Cancer Diagnostics (since 2002)
(Clinical Chemistry. 2002;48:1272-1278.)
© 2002 American Association for Clinical Chemistry, Inc.

Measurement of Prostate-specific Antigen by Use of a Novel Blood Collection and Analytical System

Barbara R. Grzedaa1, Tuan Le Bui1, Cheryl N. Warner1, Tracy L. Pirucki1, Lisa M. Dewey1, Milan Babich1 and Jack A. Maggiore1

1 BIOSAFE Laboratories, Inc., 8600 W. Catalpa Ave., Chicago, IL 60656.

aAuthor for correspondence. Fax 773-693-0410; e-mail bgrzeda{at}ebiosafe.com.

Background: Prostate-specific antigen (PSA) is widely used in the detection and monitoring of prostate cancer. We developed a system for the self-collection and transport of capillary whole blood for PSA analysis, with the goal of reducing phlebotomy visits and, thus, increasing the access and utilization of PSA in prostate cancer screening and monitoring.

Methods: The blood collection device [BIOSAFE Blood Transport System (BTSTM)] collects 70 µL of blood through a heparin-coated material into 200 µL of stabilizing solution. The diluted whole blood is used for measurement of PSA by a modified version of the Hybritech® Tandem-MP PSA Assay. Results were compared for matched samples of professionally and self-collected BTS blood and for matched BTS samples sera from blood collected by venipuncture. Imprecision for the whole-blood PSA measurement was estimated from analysis of whole-blood controls in duplicate, twice per day, over 20 days.

Results: BTS samples (n = 140) collected by a qualified healthcare professional compared with serum samples yielded the regression equation: y =1.02x + 0.04 (Sy|x = 0.35; r = 0.99). Comparison of the results for samples (n = 128) collected by the patient without professional assistance with serum samples yielded: y = 1.08x + 0.02 (Sy|x = 0.31; r = 0.99). The between-run CVs at 0.069, 0.53, 2.9, and 10.7 µg/L were 21%, 6.0%, 3.5%, and 3.8%, respectively. PSA was stable in BTS samples stored for 21 days at 18–24 °C and for 7 days at 37 °C.

Conclusion: The BIOSAFE BTS system allows accurate and convenient measurement of circulating PSA by a precise method for diluted whole blood.




The following articles in journals at HighWire Press have cited this article:


Home page
 Clin. Chem.Home page
S. A.R. Kort, A. A. Bouman, M. A. Blankenstein, and A. Bokenkamp
Cystatin C Can Be Measured Reliably in Capillary Blood Samples
Clin. Chem., May 1, 2005; 51(5): 903 - 904.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2002 by the American Association for Clinical Chemistry.